Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 18/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 16/20 | 0.61 |
| ▸ | GRK5 | P34947 | 14/20 | 0.61 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.61 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.61 |
| ▸ | GRK1 | Q15835 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568374 | 0.88 | GRK2 (0.60) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL12162716 | 0.88 | GRK2 (0.63) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2566279 | 0.86 | GRK2 (0.67) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2565505 | 0.83 | GRK2 (0.82) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2567041 | 0.82 | ROCK1 (0.60) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2566824 | 0.81 | GRK2 (0.63) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2567360 | 0.81 | GRK2 (0.63) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2566502 | 0.81 | GRK2 (0.68) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2567942 | 0.80 | GRK2 (0.69) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2567568 | 0.80 | GRK2 (0.80) | GRK2ROCK1GRK5RPS6KB1RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633740-B1 | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-09 | — | — | EP | claimed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | claimed |
| EP-1633740-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | claimed |
| JP-2007516173-A | — | — | 2007-06-21 | — | — | JP | claimed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | claimed |
| EP-1633740-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004112719-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | claimed |
| EP-1633740-B1 | 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1633740-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
| EP-1633740-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004112719-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099944-A1 | Chemical compounds | ROCK1, ROCK2, CIT | GRK2 165/4885ROCK1 1/4885GRK5 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.